{"created_at": "2021-10-07T23:07:14.000Z", "text": "RT @DividendWave: $ABBV has been hiding value (when screening for P/E) by having a wide gap between Net income and Cash flow / FCF\n\nP/E and\u2026", "id": "1446250795154935808", "author_id": "112618147"}
{"created_at": "2021-10-07T23:53:39.000Z", "text": "RT @Dividend_Dollar: \ud83d\ude80 10 TOP Dividend Growth Stocks\n\n\ud83d\udc8a $ABBV\n\ud83c\udf4e $AAPL\n\ud83d\udcf1 $AVGO\n\u2615\ufe0f $SBUX\n\ud83d\udcb3 $V\n\ud83d\udee0\ufe0f $HD\n\ud83e\uddf0 $LOW\n\ud83c\udfe6 $JPM\n\ud83d\udcbb $MSFT\n\ud83d\uded2 $COST", "id": "1446262478342553600", "author_id": "1352321041545089024"}
{"created_at": "2021-10-07T12:19:37.000Z", "text": "$ABBV AbbVie's Upadacitinib (RINVOQ\u00ae) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis", "id": "1446087819856855040", "author_id": "1262114478986010632"}
